Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.35 |
| ▸ | ESR1 | P03372 | 12/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806404 | 0.79 | ESR2 (0.39) | ESR2ESR1MAOBNPC1MAPT | |
| SCHEMBL6806169 | 0.70 | MAOA (0.46) | ESR2ESR1MIFMAOB | |
| SCHEMBL6800875 | 0.70 | ESR2 (0.38) | ESR2ESR1MIFMAOBNPC1 | |
| SCHEMBL6796152 | 0.69 | SMN1; SMN2 (0.53) | ESR2ESR1MAPK14MIFMAOB | |
| SCHEMBL6798794 | 0.69 | HTR2A (0.47) | ESR2ESR1MAPK14MIFMAOB | |
| SCHEMBL6802318 | 0.68 | ESR2 (0.41) | ESR2ESR1MAOB | |
| SCHEMBL6801825 | 0.67 | ESR2 (0.41) | ESR2ESR1NPC1MAPTRAB9A | |
| SCHEMBL6806282 | 0.67 | ESR2 (0.41) | ESR2ESR1NPC1MAPTRAB9A | |
| SCHEMBL6798576 | 0.67 | MIF (0.54) | ESR1MIFMAOB | |
| SCHEMBL6798898 | 0.65 | SMN1; SMN2 (0.43) | ESR2ESR1MIFMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ESR2 5/4885ESR1 19/4885MAPK14 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.